GRACEcast
Oncology experts summarize current and emerging issues in cancer management for patients and caregivers. Information from the Global Resource for Advancing Cancer Education (GRACE) helps people to become informed partners in their care.
Visit Show Website http://cancerGRACE.org/Recently Aired
-
HD
BRAF: A New Target to Treat in Lung Cancer
A study released at ASCO 2015 showed that the BRAF ...
A study released at ASCO 2015 showed that the BRAF V600E mutation had a high response rate to combination therapy Tafinlar (dabrafenib) plus Mekinist (trametinib), which led the doctors to agree that BRAF testing in lung cancer should become commonplace.
-
HD
Improved Survival in Malignant Pleural Mesothelioma with Avastin Added to Chemotherapy
A French study presented at ASCO 2015 showed a survival ...
A French study presented at ASCO 2015 showed a survival benefit with Avastin (bevacizumab) added to standard chemo, unlike a prior US study. The doctors discuss the influence of this trial and future potential benefits from immunotherapy in mesothelioma.
-
HD
Which Patients with Lung Cancer Should Receive Whole Brain Radiation Therapy?
Managing brain metastases is a big concern for lung cancer ...
Managing brain metastases is a big concern for lung cancer patients. The doctors discuss the drawbacks of whole brain radiotherapy and the fact that there are still unknowns regarding more targeted stereotactic radiosurgery.
-
HD
Can We Do Better with a New Chemotherapy for Squamous Cell NSCLC?
A Japanese study of squamous cell carcinoma showed value in ...
A Japanese study of squamous cell carcinoma showed value in nedaplatin vs cisplatin/Taxotere (docetaxel). But with differences in how Asian versus Caucasian patients metabolize chemotherapy, can we presume this benefit would exist for everyone?
-
HD
RET in Lung Cancer: The Next Big Target?
A trial studying Cometriq (cabozantinib) for RET rearrangements showed a ...
A trial studying Cometriq (cabozantinib) for RET rearrangements showed a promising response rate, which led the doctors to discuss if they think RET is going to be the next actionable target in lung cancer.
-
HD
Adding to Tarceva in a Broad NSCLC Population: Weighing Benefits with Risks
A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest ...
A trial comparing Tarceva (erlotinib) to Cometriq (cabozantinib) showed modest benefit for EGFR wild type patients, but the challenging side effect profile should lead us to question if we can identify only patients most likely to benefit from Cometriq.
-
HD
Debating EGFR Inhibitors for Squamous Cell Lung Cancer Patients
Squamous cell carcinoma patients have limited options. Data presented at ...
Squamous cell carcinoma patients have limited options. Data presented at ASCO 2015 showed positive patient outcomes with Gilotrif (afatinib) vs Tarceva (erlotinib), but some feel that there is little value in a treatment with only modestly better results.
-
HD
Small Cell Lung Cancer Patients Can Benefit from Immunotherapy
The current standard of care for SCLC shows limited results ...
The current standard of care for SCLC shows limited results with high toxicities. Drs. Soria, Gandhi, and West discuss new ASCO 2015 data that show promise for a subset of patients with PD-L1 expression on Keytruda (pembrolizumab) or Opdivo (nivolumab).
-
HD
Immunotherapy Combinations: Best Balance of Activity and Tolerability?
As more immunotherapeutics become available to treat lung cancer, research ...
As more immunotherapeutics become available to treat lung cancer, research must determine how to balance efficacy, toxicities, and cost. That means finding which patients who will benefit from which drugs while maintaining good quality of life.
-
HD
Choices Among Immunotherapeutics May Be the Future of Lung Cancer Care
Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) ...
Novel immunotherapy agent atezolizumab (MPDL3280A) looks superior to Taxotere (docetaxel) in a study, specifically for patients with PD-L1. What are the implications of multiple agents with similar mechanisms of action in the same clinical settings?
